Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

Molecular Cancer Therapeutics

Volumn 6, Issue 4, 2007, Pages 1198-1211

  Sharp, Swee Y ^a   Prodromou, Chrisostomos ^b   Boxall, Kathy ^a   Powers, Marissa V ^a   Holmes, Joanna L ^a   Box, Gary ^a   Matthews, Thomas P ^a   Cheung, Kwai Ming J ^a   Kalusa, Andrew ^a   James, Karen ^a   Hayes, Angela ^a   Hardcastle, Anthea ^a   Dymock, Brian ^c   Brough, Paul A ^c   Barril, Xavier ^c   Cansfield, Julie E ^c   Wright, Lisa ^c   Surgenor, Allan ^c   Foloppe, Nicolas ^c   Hubbard, Roderick E ^c   Aherne, Wynne ^a   Pearl, Florence ^b   Jones, Keith ^a   McDonald, Edward ^a   Raynaud, Florence ^a   Eccles, Sue ^a   Drysdale, Martin ^c   Workman, Paul ^a   more..

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Vernalis PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 3,4 DIARYLPYRAZOLE RESORCINOL; ADENOSINE TRIPHOSPHATASE; AMIDE; B RAF KINASE; CCT 018159; CT 018159; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; ISOXAZOLE DERIVATIVE; PROTEIN ARGININE METHYLTRANSFERASE; PYRAZOLE DERIVATIVE; RADICICOL; RAF PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESORCINOL DERIVATIVE; SURVIVIN; UNCLASSIFIED DRUG; VER 49009; VER 50589;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BINDING ASSAY; BINDING COMPETITION; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN HCT116; CONTROLLED STUDY; DISEASE MODEL; DISSOCIATION CONSTANT; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TUMOR LEVEL; ENTHALPY; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; ISOTHERMAL TITRATION CALORIMETRY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; WEIGHT REDUCTION; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATASES; ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CELL CYCLE; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; FEMALE; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HT29 CELLS; HUMANS; ISOXAZOLES; MICE; MICE, NUDE; NAD(P)H DEHYDROGENASE (QUINONE); PROTEIN BINDING; PYRAZOLES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34248166042     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0149     Document Type: Article

References (60)

1. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3-24.
2. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
4. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004;206: 149-57.
5. da Rocha DS, Friedlos F, Light Y, et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005;65:10686-91.
6. Grbovic OM, Basso AD, Sawai A, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A 2006;103:57-62.
7. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425: 407-10.
8. Obermann WM, Sondermann H, Russo AA, Pavletich NP, Hartl FU. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 1998;143:901-10.
9. Panaretou B, Prodromou C, Roe SM, et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 1998;17:4829-36.
10. Schulte TW, An WG, Neckers LM. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 1997;239:655-9.
11. Connell P, Ballinger CA, Jiang J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001;3:93-6.
12. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-15.
13. Agatsuma T, Ogawa H, Akasaka K, et al. Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg Med Chem 2002;10:3445-54.
14. Egorin MJ, Lagattuta TF, Hamburger DR, et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 2002;49:7-19.
15. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
16. Guo W, Reigan P, Siegel D, et al. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 2005;65:10006-15.
17. Glaze E, Smith A, Johnson D, et al. Dose range-finding toxicity studies of 17-DMAG. Proceedings of American Association of Cancer Research 2003;44:162-3.
18. Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006;103:17408-13.
19. Soga S, Shiotsu Y, Akinaga S, Sharma SV. Development of radicicol analogues. Curr Cancer Drug Targets 2003;3:359-69.
20. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006;95:323-48.
21. Janin YL. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? J Med Chem 2005;48:7503-12.
22. Chiosis G, Rodina A, Moulick K. Emerging Hsp90 inhibitors: from discovery to clinic. Anticancer Agents Med Chem 2006;6:1-8.
23. Roe SM, Prodromou C, O'Brien R, et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999;42:260-6.
24. Chiosis G. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 2006;6:1183-91.
25. Chiosis G, Caldas LE, Solit D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr Opin Investig Drugs 2006;7:534-41.
26. Cheung KM, Matthews TP, James K, et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005;15:3338-43.
27. Sharp SY, Boxall K, Rowlands M, et al. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 2007;67: 2206-16.
28. Smith NF, Hayes A, James K, et al. Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Mol Cancer Ther 2006;6:1628-37.
29. Dymock BW, Barril X, Brough PA, et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 2005;48:4212-5.
30. Drysdale M, Dymock B, Finch H, et al. Isoxazole compounds as inhibitors of heat shock proteins. 2004; pp. 1-180. [Eur. Pat. Off. No. WO 2004/ 072051 A1].
31. Wright L, Barril X, Dymock B, et al. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol 2004;11: 775-85.
32. Panaretou B, Siligardi G, Meyer P, et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 2002;10:1307-18.
33. Rowlands MG, Newbatt YM, Prodromou C, et al. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 2004;327:176-83.
34. Howes R, Barril X, Dymock BW, et al. A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem 2006;350:202-13.
35. Sanderson S, Valenti M, Gowan S, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 2006;5:522-32.
36. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61: 4003-9.
37. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-ordinating Committee on Cancer Research guidelines for the welfare of animals in experimental neoplasia. 2nd ed. Br J Cancer 1998;77:1-10.
38. Raynaud FI, Whittaker SR, Fischer PM, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005;11:4875-87.
39. Eccles SA, Court WJ, Box GA, et al. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res 1994;54:5171-7.
40. Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63:5224-9.
41. Hardcastle A, Boxall K, Richards J, et al. Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90. Assay Drug Dev Technol 2005;3:273-85.
42. Cummings J, McArdle CS. Studies on the in vivo disposition of Adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer 1986;53:835-8.
43. Sharp SY, Kelland LR, Valenti MR, et al. Establishment of an isogenic human colon tumor model for NQ01 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 2000;58:1146-55.
44. Sharp SY, Rowlands MG, Jarman M, Kelland LR. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and - resistant human ovarian carcinoma cell lines. Br J Cancer 1994;70:409-14.
45. Sharp SY, O'Neill CF, Rogers P, Boxall FE, Kelland LR. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. Eur J Cancer 2002;38:2309-15.
46. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
47. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner.
48. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001;7:2155-8, 2228-36.
49. Hickey E, Brandon SE, Potter R, et al. Sequence and organization of genes encoding the human 27 kDa heat shock protein. Nucleic Acids Res 1986;14:4127-45.
50. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000;92: 1564-72.
51. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 2000;97:10832-7.
52. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62.
53. Maloney A, Clarke P, Naaby-Hansen S, et al. Gene and protein expression profiling of human ovarian cancer cells treated with the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG). Cancer Res 2007;67:3239-53.
54. Palm K, Luthman K, Ungell AL, et al. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem 1998;41: 5382-92.
55. Modi S, Stopeck A, Gordon MS, et al. Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T). J Clin Oncol (Meeting Abstracts) 2006;24:501.
56. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42:273-9.
57. Bagatell R, Paine-Murrieta GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000;6:3312-8.
58. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A 2003;100:13791-6.
59. Paduano F, Villa R, Pennati M, et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 2006;5:179-86.
60. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S. Human SWI/ SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 2004;24:9630-45.